OR WAIT null SECS
COTA’s real-world data and Kite's drug development pipeline will complement single-arm clinical trials to accelerate cancer research benefiting patients.
A new collaboration to help inform decisions about future therapeutic applications for blood cancers while inspiring new ways of thinking about how clinical trials are designed has been recently announced by COTA, Inc and Kite.
COTA, Inc., an oncology real-world data and analytics company, is working with Kite, a Gilead company, through which COTA’s real-world data will be used to accelerate Kite’s drug development pipeline, according to a release.
The use of real-world data (RWD) is expanding as it's increasingly used in a complementary role to support, clarify, or accelerate randomized clinical trials. Kite will work closely with oncologists, data scientists, and researchers at COTA to develop and validate real-world endpoints and accelerate the clinical development timeline for cancer patient's benefit.
“At COTA, we pride ourselves not just on the high quality of the data we deliver to our partners, but also on our ability to collaborate with sponsors to inform clinical research and get the best drugs to patients more efficiently,” said Mike Doyle, CEO of COTA. “With the support of the FDA, Kite and many others, COTA is helping to pioneer the use of RWD in clinical research with the ultimate goal of accelerating clinical development, reducing healthcare costs, and helping cancer patients live longer, healthier lives.”
COTA provides comprehensive and diverse cancer RWD to leading life sciences and healthcare provider organizations that are caring and developing treatments for patients living with a wide range of cancers. The organization combines its oncology expertise with technology-enabled human data abstraction to curate meaningful, longitudinal, and de-identified patient data.
As RWD is increasingly applied in clinical development, COTA’s customized data sets can help increase patient diversity in clinical trials; expand indications of already approved drugs; replace the traditional standard-of-care or placebo group via a RWD-powered synthetic control arm; and empower life sciences companies to make faster decisions on their pipeline.